Oscar rises after upbeat guidance offsets underwhelming Q4 results
I'm PortAI, I can summarize articles.
Oscar Health's stock rose in premarket trading following its optimistic full-year guidance, despite disappointing Q4 results. For Q4 2025, Oscar reported a loss per share of $1.24 and revenue of $2.8 billion, both below analyst expectations. However, for 2026, the company forecasts revenues between $18.7 billion and $19 billion, significantly higher than the $12.4 billion anticipated by analysts, and a medical cost ratio better than expected. The health insurance sector has faced challenges due to rising costs and the expiration of tax credits for ACA Marketplace plans.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Sherwoodnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments